Pfizer to raise prices on 41 drugs in 2019

Amy Baxter | November 16, 2018 | Health Exec | Policy & Regulations

Researchers found millions of heart failure patients who qualify for standard, guideline directed medical therapies, but did not receive it due to poor health literacy, limited access to care and medication costs.

Drug manufacturer Pfizer announced it would raise the prices of 41 drugs in January 2019, The Wall Street Journal reported. The move comes after the company committed to not raising prices in 2018 after coming under fire from President Trump. That commitment did not extend into 2019.

Most of the increases will be 5 percent, though one drug’s price will jump 9 percent, while three will only increase 3 percent, the WSJ reported. Most of the company’s portfolio of prescription drugs––90 percent––won’t be impacted by the price increases.

Rising drug prices have become a hot topic for the Trump administration, which has taken several steps to challenge the drug industry.

See the full story below:

Pfizer to Raise Prices on 41 Drugs in January

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

Cardiovascular Business

FDA commissioner urges clinicians to join fight against medical misinformation

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

AI in Healthcare

4 points crucial to the nimble regulation of GenAI

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Cardiovascular Business

Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more.

Pfizer to raise prices on 41 drugs in 2019

Related Content

Around the web